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esveratrol is a phytoalexin that is naturally produced by various plants and is present in grapes, peanuts, blueberries, and hops (1) (2) (3) (4) . Resveratrol is often produced as a defense against microbial infections by Botrytis cinerea (5) , radical damage, UV irradiation (6) , and other stressors. The trans and cis configurations of resveratrol exist in glucosides, dimers (pallidol) (7), trimers (grandiphenol C) (8) , ␣-viniferin (9), and polymers ( Fig. 1) . Moreover, the biological activities of resveratrol are mostly associated with its trans configuration (10) (11) (12) . Other postmodified resveratrol derivatives with potent biological activities, such as antioxidant, cardioprotective, neuroprotective, anticancer, antiestrogenic, and antiaging properties, have also been identified in different plant sources, including pterostilbene, trans-polydatin (trans-piceid), piceatannol (synonym astringinin), and astringin ( Fig. 1) (12) (13) (14) .
Due to the popularity of the "French paradox," a wide array of studies on resveratrol have been performed. As a result, the biological activities of resveratrol against various diseases, including type II diabetes (15) (16) (17) , obesity, atherosclerosis (18, 19) , Alzheimer's disease (20) , cardiovascular diseases (including hypertension [21, 22] and ischemic injury [23] [24] [25] ), and various cancers (26) , have been demonstrated. Similar to other antioxidants, resveratrol neutralizes self-generated free radical species, including reactive oxygen species and reactive nitrogen species, and prevents radical damage to organs. Thus, most of the biological activities of resveratrol are attributed to its intrinsic radical-scavenging activity (27) . Resveratrol exhibits anti-inflammatory properties, as demonstrated by its ability to inhibit the production of nitric oxide (NO) and proinflammatory cytokines, including tumor necrosis factor alpha and interleukin-6 (IL-6), from macrophages (28) (29) (30) . Resveratrol also has numerous functional targets inside cells, including receptors (either membrane bound or intracellular), signaling molecules (sirutins [31] and the 5=-AMP-activated kinase signaling pathway [32] ), transcription and DNA repair factors, and oxidative enzymes (33, 34) . Furthermore, based on the database available at the U.S. National Institutes of Health website (http://www.clinicaltrials.gov/), a series of clinical investigations of resveratrol are in progress, as well. However, additional studies are needed to address the safety, pharmacokinetics, pharmacodynamics, and clinical efficacy of resveratrol, as these parameters are essential for the advancement of resveratrol for clinical application (35) .
Most biologically active natural products (NPs) and recently used therapeutics, including calicheamicin (36), daunomycin (37) , streptomycin (38) , vancomycin (39) , digitotoxin (40) , and amphotericin (41) , are decorated with diverse types of sugar moieties to enhance their physical, chemical, and biological properties. These added sugar moieties can also be important for the recognition of different target molecules in a cell (42) . Moreover, the adsorption, distribution, metabolism, and excretion properties of drugs are also influenced by the type of sugar moiety attached to them (43) . Hence, glycosylation has been developed as an efficient tool for generating biologically potent and novel NP glycoside compounds with enhanced drug efficacy.
Various NPs have been successfully glycodiversified, either by enzymatic or by chemical synthesis approaches. Digitoxin (44) , novobiocin (45) , vancomycin (46) , colchicine (47) , and 4-methyl-umbelliferone (48) have been glycorandomized, thereby producing a number of unusual sugar-bearing NPs. Among these, some have shown enhanced biological properties compared to their respective parent molecules (44) . In addition, glycosyltransferases (GTs) (e.g., oleandomycin GT [OleD] and its variants [49, 50] , kanamycin GT-KanE, and vancomycin GT-GtfE [51] ) have been engineered to increase their flexibility in accepting various donor and acceptor substrates. For the present study, a GT, YjiC (GenBank accession no. AAU40842.1) from Bacillus licheniformis DSM 13, with a flexible donor and acceptor substrate profile was selected in order to synthesize glycodiversified resveratrol derivatives. YjiC has been shown to accept geldanamycin analogues (52) , epothilone A (53), various flavonoids (54, 55) , chalcone (56) , and isoflavonoids (57) as substrates for glucosylation. In this study, resveratrol was used as an acceptor substrate and various rare nucleotide diphosphate sugars were used as sugar donor substrates to produce glycodiversified resveratrol derivatives that have not been previously described.
reaction product was directly monitored by high-performance liquid chromatography (HPLC) coupled with a photodiode array (PDA) after proper dilution.
Preparative-scale reaction of resveratrol with UDP-D-glucose. The reaction mixture contained purified YjiC enzyme (500-g/ml final concentration in the reaction mixture), 20 mmol (final concentration) of UDP-D-glucose (ϳ122 mg) as a donor substrate, 5 mmol resveratrol (11.4 mg dissolved in dimethyl sulfoxide [DMSO] ) as an acceptor substrate, and 100 mmol Tris-Cl (pH 8.0) buffer containing 10 mmol MgCl 2 · 6H 2 O. The reaction was carried out in a 10-ml final volume for 12 h at 37°C and stopped by adding a triple volume of chilled methanol. Then, the reaction mixture was mixed by vortexing and centrifuged at 12,000 rpm for 30 min at 4°C to remove denatured protein. The supernatant was concentrated by evaporation and lyophilization. Finally, the compounds were dissolved in 2 ml HPLC grade methanol and subjected to preparative HPLC purification (Shimadzu, Tokyo, Japan). The purified compounds were dried, lyophilized, and dissolved in methanol-D 4 and further analyzed by nuclear magnetic resonance (NMR).
Deglycosylation reaction assay. The deglycosylation assay was carried out using purified resveratrol 3-O-␤-D-glucoside as the substrate. The reaction mixture contained 100 mmol Tris-Cl (pH 8.0), 10 mmol UDP, 10 mmol MgCl 2 , and a 50-g/ml final concentration of enzyme. The reaction mixture was incubated at 37°C for 24 h. Ten microliters of reaction sample was taken and analyzed by HPLC-PDA after proper dilution.
Analytical methods. For the thin-layer chromatography (TLC) analysis of reaction mixtures, samples were loaded on a normal-phase silica TLC plate and developed in an ethyl acetate-methanol-water-toluene (10: 2:1.5:0.2 ml) mixture in a closed TLC chamber. After a complete run of the samples, the plate was air dried and visualized under UV light (UV) at 254 nm. The reverse-phase HPLC-PDA analysis was performed with a C 18 column (YMC-Pack ODS-AQ; 4.6 mm internal diameter [i.d.], 150 mm long, 5 m particle size) connected to a PDA (308 nm) using binary conditions of H 2 O (0.1% trifluoroacetic acid buffer) and 100% acetonitrile (ACN) at a flow rate of 1 ml/min for 25 min. The ACN concentrations were as follows: 20% (0 to 5 min), 50% (5 to 10 min), 70% (10 to 15 min), 90% (15 to 20 min), and 10% (20 to 25 min). The purification of compounds was carried out by preparative HPLC with a C 18 column (YMCPack ODS-AQ; 150 mm long, 20 mm i.d., 10 m particle size) connected to a UV detector (308 nm) using a 36-min binary program with ACN at 20% (0 to 5 min), 40% (5 to 10 min), 40% (10 to 15 min), 90% (15 to 25 min), 90% (25 to 30 min), and 10% (30 to 35 min) at a flow rate of 10 ml/min. The high-resolution quantitative time of flight electrospray ionization mass spectrometry (HRQTOF-ESI-MS) was carried out in positive ion mode on an Acquity mass spectrometer (with UPLC; Waters, Milford, MA, USA) coupled with a Synapt G2-S system (Waters). The compounds were further characterized with a 900-MHz Avance II 900 Bruker (Germany) BioSpin NMR spectrometer equipped with a TCI CryoProbe (5 mm). All the samples were prepared in methanol-D 4 (Sigma-Aldrich). One-dimensional NMR ( 1 H-NMR and 13 C-NMR) and two-dimensional NMR (correlation spectroscopy [COSY], nuclear Overhauser effect spectroscopy [NOESY], rotating-frame NOE spectroscopy [ROESY], heteronuclear single-quantum correlation [HSQC] , and heteronuclear multiple-bond correlation [HMBC] ) were performed to elucidate the structures of the resveratrol glucosides. For 1 H-NMR experiments, 16 transient spectra were acquired with a spectral width of 9,014.423 Hz (10 ppm). For 13 C-NMR experiments, 512 transient spectra were acquired with a spectral width of 56,818.184 Hz (250 ppm). The pulse sequences for each NMR were as follows:
1 H-NMR, zg30 or zgpr (water suppression); 13 C-NMR, zgpg30; COSY, cosygpqf; ROSEY, roseyesgp; HSQC, hsqcetgpsi; and HMBC, hmbcgplpndqf. All the raw data were processed by using TopSpin 3.1 software (Bruker) and further analyzed by using MestReNova 8.0 software (Mestrelab Research S. L., Spain).
Molecular modeling and docking of resveratrol in YjiC. Discovery Studio v. 3.1 (2011) (DS 3.1) was used for homology-modeling and docking studies of YjiC protein (Accelrys, San Diego, CA, USA). PSI-BLAST (comparison matrix, BLOSUM 62; E threshold, 10) was carried out using the ExPASy (Expert Protein Analysis System; 2010) server (http://ca .expasy.org) to search the homologs of YjiC. A template, OleD (Protein Data Bank [PDB] ID 2IYA; crystal structure resolved at 1.7 Å) from Streptomyces antibioticus, was selected to build the model on the basis of high similarity and identity with YjiC. An approach similar to one previously described was followed to construct and validate the YjiC model (58) . The amino acid sequence of YjiC was aligned with that of OleD and used for the model construction using the "build homology model" command and MODELLER (59) , applying the Accelrys CHARMm force field throughout the process of modeling. The refined model was validated with ProSA 2003 and Ramachandran Plot7 (58) . Root mean square deviation (RMSD) analysis of the YjiC model was done using SUPERPOSE (60) . Resveratrol was docked to the validated model of YjiC using the "LigandFit" procedure implemented in Discovery Studio (61) . Twenty-five different conformations were generated for the selection of the best binding mode of resveratrol in the YjiC protein (Carlo trails). The conformations of each ligand were fitted in the binding cavity of YjiC with a grid-based energy function. The docked structures (diverse conformations) were saved, and a scoring function was applied to each docked structure (binding affinity prediction). All the conformations were scored using the Discovery Studio 3.1 scoring function, which includes Ligscore 1, Ligscore 2, Piecewise Linear Potential 1 (PLP1), PLP2, Jain, and Potential of Mean Force (PMF). Out of 25 conformations generated, the most suitable docking mode for resveratrol with a high score from the consensus scoring function was finally selected.
RESULTS

Enzymatic synthesis of resveratrol glucosides.
The HPLC-PDA analysis of the reaction mixture containing resveratrol, UDP-Dglucose, and the YjiC enzyme showed four different glucoside peaks at 308 nm (Fig. 2) . By analyzing the same reaction mixture with an HPLC-PDA combined with HRQTOF-ESI-MS, the exact mass for each peak was determined. Peaks P I and P II had retention times (t R s) of 13.32 min and 12.9 min, respectively. Both peaks had an exact mass [(P I or P II ) ϩ H ϩ ] of ϳ391.1384 and represented monoglucosides of resveratrol. The third peak (P III ) had a t R of 11.4 min with an exact mass, [P III ϩ Na ϩ ], of ϳ575.1755 and represented a resveratrol with two glucoses conjugated. Similarly, the fourth peak (P IV ) had a t R of 10.1 min and an exact mass, [P IV ϩ Na ϩ ], of ϳ737.2266, representing a triglucoside of resveratrol (see Fig. S1 and Tables S1 and S2 in the supplemental material). To further characterize the reaction products obtained, a preparative-scale reaction was carried out in a 10-ml reaction volume. The products were purified as described in Materials and Methods and were subjected to various NMR analyses, including 1 H-NMR, 13 C-NMR, and two-dimensional NMR analyses (COSY, NOESY, ROESY, HSQC, and HMBC) (see Fig. S2 to S4 in the supplemental material). The P I product was identified as (E)-1-(3-␤-D-glucopyranosyloxy-5-hydroxyphenyl)-2-(4-hydroxyphenyl) ethene (common name, resveratrol 3-O-␤-D-glucoside) (1.81 mg; 465 mol; ϳ9.3%), which has previously been identified from different plant sources, as well as by enzymatic reactions (62, 63) . The P II product was identified as (E)-1-(3,5-dihydroxyphenyl)-2-(4-␤-D-glucopyranosyl-oxyphenyl) ethene (common name, resveratrol 4=-O-␤-D-glucoside) (3.63 mg; 931.5 mol; ϳ18.6%), as described previously (62, 63) . According to the mass analysis performed, P III is hypothesized to represent a diglucoside of resveratrol identified as (E)-1- (Fig. 2) . The purity of each product was greater than 95%, and the overall conversion rate of resveratrol to its glucoside forms was 89.92%. In addition, YjiC exhibited nonregiospecific enzyme activity by conjugating glucose at all the available reactive hydroxyl positions of resveratrol. In our previous report, YjiC exhibited high flexibility when phloretin was used as an acceptor molecule, producing five different glucosylated derivatives, including two monoglucosides, two diglucosides, and a triglucoside. Recently, Zhou and colleagues reported the production of two monoglucosides and two diglucosides of resveratrol using OleD and its variants (ASP, AIP, TDP16, and 3-1-H12) (63) . However, the authors did not report the detection of a triglucoside resveratrol.
Biosynthesis of diverse resveratrol glycosides. To characterize the donor substrate specificity of YjiC for different NDP sugars using resveratrol as an acceptor substrate, NDP-D-sugars and NDP-L-sugars were used in glycosyltransferase assays. For the NDP-D-sugars, four different types of sugar donors were used. Specifically, C-2 position-modified sugars (TDP-D-2-deoxyglucose and UDP-N-acetylglucosamine), a C-4 position-modified sugar (UDP-D-galactose), a C-6 position-modified sugar (UDP-D-glucuronic acid), and a C-4 and C-6 position-modified sugar (TDP-D-viosamine) were used. Two different NDP-L-sugars, TDP-L-rhamnose and GDP-L-fucose, were also used to assay the activity of YjiC with resveratrol under identical reaction conditions. As a preliminary analysis, TLC on normal-phase silica plates (F 254 ; Merck, Darmstadt, Germany) was performed. Extra spots with a lower t R than that of unmodified resveratrol were distinctly observed in most of the reaction mixtures (see Fig. S5 in the supplemental material). All the reaction mixtures were further analyzed by HPLC-PDA (Fig. 3) , which detected the conjugation of various sugars with resveratrol at 308 nm. HPLC-PDA and HRQTOF-ESI-MS analysis in positive mode finally confirmed the conjugation of various sugars with resveratrol ( Fig. 3 ; see Fig. S6 and Tables S1 and S2 in the supplemental material).
Because of the limited availability and difficulties in enzymatic synthesis of various NDP sugars, all products were characterized by HPLC-PDA followed by HRQTOF-ESI-MS, with t R s for glycorandomized products compared with those of the aforementioned glucosylated products of resveratrol that were structurally characterized using various NMR analyses ( Fig. 3 ; see Table S1 in in the supplemental material). These products had t R s similar to that of resveratrol 3-O-␤-D-glucoside (see Table S1 in the supplemental material). The substrate conversion percentage, as well as the number of products formed, varied with the NDP sugars used in the reaction mixtures. The conversion percentages of resveratrol to resveratrol glycosides were determined at different time intervals in all reaction mixtures (Fig. 4) . The highest conversion of resveratrol to resveratrol glucosides was obtained with UDP-D-glucose (ϳ90%), followed by TDP-D-viosamine (ϳ49%), UDP-D-galactose (ϳ45%), and TDP-2 deoxy-D-glucose (ϳ45%). In comparison, the reactions that used TDP-L-rhamnose and GDP-L-fucose exhibited the lowest conversion (21.6% and 15.4%, respectively) of resveratrol. The reaction mixtures that used UDP-D-glucuronic acid and UDP-D-N-acetylglucosamine did not exhibit any conversion of resveratrol to its glycoside derivatives. The conversion percentage of resveratrol to the respective resveratrol glycosides increased in all the reactions upon longer incubation (Fig. 4) . However, an unexpected result was that the concentration of resveratrol 3-O-␤-D-glucoside was higher after a 1-h incubation period and lower concentrations were detected after 2 h and 3 h of incubation (data not shown). This decrease in the amount of product initially formed could be due to the instability of the product, or the product may be readily converted to resveratrol and UDP-D-glucose in a reverse-glycosylation reaction mediated by YjiC as previously reported for phloretin glycosylation (56) . In addition, the product However, resveratrol 3,5,4=-O-␤-D-triglucoside was not detected, and this may be due to a lack of excess UDP-D-glucose in the reaction mixture. Taken together, these results indicate that YjiC can deglucosylate resveratrol glucoside to produce UDP-D-glucose and resveratrol, and these products can eventually be utilized by the same enzyme to produce other products (Fig. 5) .
Docking of resveratrol in the YjiC model. OleD from S. antibioticus (PDB ID 2IYA) (65) was selected as a template to build the YjiC model using Accelrys Discovery Studio 3.1 software (Accelrys Inc., San Diego, CA) based on the high similarity and identity of the amino acid sequences (see Fig. S7 in the supplemental material). The three-dimensional (3D) structure of the YjiC model resembles the Rossmann-like domains belonging to the GT-B fold of GT1 family proteins (Fig. 6A) . Following active-site optimization, molecular dynamics were used to dock resveratrol to the YjiC model. The study of all docked conformations of resveratrol in the YjiC model showed that resveratrol has two binding modes (head first versus tail first) (Fig. 6) . In head-first mode, 3-OH and 5-OH groups were in close proximity to UDP in a deep cleft formed between N-terminal (acceptor binding pocket) and C-terminal (donor binding pocket) domains. In the tail-first mode, the 4=-OH group was near the UDP (Fig. 6B and C) . Thus, there was a possibility of production of multiple glycosylated products of resveratrol. This in silico docking result is consistent with our in vitro glucosylation reaction elucidating the production of four different resveratrol glucoside derivatives while using UDP-D-glucose as a glucose donor substrate (Fig. 2) , as well as the conjugation of other sugars at different positions of resveratrol by YjiC (Fig. 3) . Similar binding modes of resveratrol were also observed in docking studies of resveratrol in OleD and its variants, producing two monoglucosides and two diglucosides of resveratrol (63) .
DISCUSSION
Besides a number of biological activities of resveratrol and its derivatives beneficial to health (12) (13) (14) , recent evidence has also demonstrated an important role of resveratrol in the activation of SIRT1, a protein that has been shown to lengthen the life spans of yeast, worms, flies, fish, and mice (31, 66, 67) . Upregulation of SIRT1 has also been shown to reduce cellular oxidative stress in the diabetic milieu (68) . In this study, we attempted to expand the number of resveratrol derivatives by means of an enzymatic glycosylation approach that could help to generate novel therapeutics. Since the YjiC glycosyltransferase has been identified as accepting diverse kinds of NDP glucoses, as well as NDP sugars, as donor substrates, the use of the same enzyme has eased the production of diverse resveratrol glucosides and glycosides by in vitro glycosylation. We have recently reported the wide promiscuity of the enzyme, which raised the possibility of production of diverse flavonol glycosides. As resveratrol is one of the most studied plantderived lead compounds and is under clinical trials for development as a drug for diverse diseases, generation of novel resveratrol glycosides could facilitate the development of drugs to treat oxidative-stress-induced diseases and to provide antiaging functions.
Resveratrol occurs in two forms, cis-resveratrol and trans-resveratrol. The latter form of resveratrol changes to the cis form upon exposure to UV light. Importantly, the trans form of resveratrol is biologically potent and more abundantly present in nature than the cis form (69) (70) (71) . The glycosylation of resveratrol could make it more stable, since most studies have proven that glycosylation enhances the stability of the compound (72) (73) (74) . Furthermore, glycosylation increases its solubility in water, which ultimately enhances the bioavailability of the compound for diverse medical and cosmetic applications. Importantly, the conjugation of resveratrol with diverse sugars could modify its biological potency, as well.
The sugar moieties of most NPs have been found to be involved in cell-cell recognition, stable binding of the compound at the target site, and other biochemical processes (42) In general, the secondary metabolites produced by plants and actinomycetes are unstable, toxic, hydrophobic, or volatile and are postmodified to glycosylated forms by GTs (75) . Moreover, these glycosylated compounds have been found to exhibit increased stability and solubility in water while also being nontoxic. Currently, the relevance of metabolic stability following deglycosylation of NP-glycosides remains unknown. Thus, the formation of resvera- The molecular modeling and docking studies showed that resveratrol has two binding modes (head first versus tail first) with YjiC, similar to OleD. The dual binding modes of resveratrol have supported the possibility of production of multiple glucosylated products. Thus, glycosylation can occur at the 3-, 5-, and 4=-hydroxyl positions of resveratrol. Our in vitro results, which included the detection of diglucoside and triglucoside forms of resveratrol, are consistent with this model. Detailed studies of protein structure, as well as mutagenesis studies, are needed to further elucidate the mechanistic details of adopting various sugars in the donor substrate binding pocket, as well as harboring the substrate in dual conformations by YjiC, which could be a key follow-up study to explore the substrate promiscuity of the enzyme. Though the biological activities of the newly synthesized resveratrol glucosides and various glycoside analogues in this study are still unknown, they could be beneficial for the generation of novel therapeutics.
